{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:30:03Z","timestamp":1760131803173},"reference-count":146,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1157\/13089670","type":"journal-article","created":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T07:59:57Z","timestamp":1149839997000},"page":"335-346","source":"Crossref","is-referenced-by-count":6,"title":["Coinfecci\u00f3n por el VIH y el virus de la hepatitis C"],"prefix":"10.1016","volume":"24","author":[{"given":"Andr\u00e9s","family":"Ruiz-Sancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13089670_bib1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1089\/08892220152644160","article-title":"Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients","volume":"17","author":"Mart\u00edn-Carbonero","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13089670_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with HIV infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1086\/319747","article-title":"Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine\/Infectious Diseases, in 1995 and 1997","volume":"32","author":"Rosenthal","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib4","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/00002030-200308150-00009","article-title":"Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)","volume":"17","author":"Rosenthal","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00126334-200310010-00006","article-title":"Hospitalization rates differ by hepatitis C status in an urban HIV cohort","volume":"34","author":"Gebo","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13089670_bib6","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.280.17.1497","article-title":"Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators","volume":"280","author":"Detels","year":"1998","journal-title":"JAMA"},{"key":"10.1157\/13089670_bib7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1157\/13089670_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","article-title":"Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease","volume":"135","author":"Murphy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1157\/13089670_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200401020-00001","article-title":"Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel","volume":"18","author":"Soriano","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-138-3-200302040-00012","article-title":"Hepatitis C in the HIV-infected person","volume":"138","author":"Sulkowski","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1157\/13089670_bib12","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/00002030-200311070-00002","article-title":"Update on chronic hepatitis C in HIV\/HCV-coinfected patients: viral interactions and therapy","volume":"17","author":"Br\u00e4u","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/432762","article-title":"Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy","volume":"192","author":"Rockstroh","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(04)01059-X","article-title":"HIV\/HCV coinfection","volume":"4","author":"Rockstroh","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1157\/13089670_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2105\/AJPH.91.1.42","article-title":"Sharing of drug preparation equipment as a risk factor for hepatitis C","volume":"91","author":"Hagan","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1157\/13089670_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/431486","article-title":"Association of unsafe sex and increased incidence of hepatitis C infection in HIV-infected men who have sex with men","volume":"41","author":"Rauch","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1468-1293.2004.00225.x","article-title":"Acute hepatitis C in HIV-infected men who have sex with men","volume":"5","author":"Ghosn","year":"2004","journal-title":"HIV Med"},{"key":"10.1157\/13089670_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/00002030-199510000-00003","article-title":"High hepatitis C viremia and impaired antibody response in patients coinfected with HIV","volume":"9","author":"Cribier","year":"1995","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V94.4.1183","article-title":"Low levels of HCV RNA in serum, plasma, and PBMCs of IDUs during long antibody-undetectable periods before seroconversion","volume":"94","author":"Beld","year":"1999","journal-title":"Blood"},{"key":"10.1157\/13089670_bib20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00126334-200210010-00005","article-title":"Hepatitis C viremia in HIV-infected individuals with negative HCV antibody tests","volume":"31","author":"George","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/infdis\/175.1.164","article-title":"The association between HCV genotype and HIV disease progression in a cohort of hemophiliacs","volume":"175","author":"Sabin","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00002030-199804000-00006","article-title":"Does HCV co-infection accelerate clinical and immunological evolution of HIV infected patients?","volume":"12","author":"Piroth","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2893.2000.00227.x","article-title":"HCV coinfection is a negative prognostic factor for clinical evolution in HIV-positive patients","volume":"7","author":"Piroth","year":"2000","journal-title":"J Viral Hepatitis"},{"key":"10.1157\/13089670_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00042737-199806000-00009","article-title":"The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users","volume":"10","author":"Haydon","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13089670_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1086\/520144","article-title":"Hepatitis C in the HAVACS: the effect of coinfection on survival","volume":"29","author":"Staples","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib26","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfections","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(00)04482-2","article-title":"HIV-1 progression in hepatitis C-infected drug users","volume":"357","author":"Soriano","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10096-002-0823-0","article-title":"Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy","volume":"21","author":"Mac\u00edas","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1157\/13089670_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease","volume":"288","author":"Sulkowski","year":"2002","journal-title":"JAMA"},{"key":"10.1157\/13089670_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1086\/345953","article-title":"Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART","volume":"36","author":"Tedaldi","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib31","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/00002030-200411050-00018","article-title":"CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use","volume":"18","author":"Dronda","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00126334-200307010-00011","article-title":"The impact of hepatitis C virus co-infection on HIV progression before and after highly active antiretroviral therapy","volume":"33","author":"Klein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13089670_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1086\/318539","article-title":"HCV load is associated with HIV-1 disease progression in hemophiliacs","volume":"183","author":"Daar","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1086\/426513","article-title":"Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease","volume":"191","author":"Yoo","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/315283","article-title":"HCV in lymphoid cells of patients coinfected with HIV-1: evidence of active replication in monocytes\/macrophages and lymphocytes","volume":"181","author":"Laskus","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib36","unstructured":"N\u00fa\u00f1ez M, Benito J, L\u00f3pez M, Gonz\u00e1lez-Lahoz J, Soriano V. Hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. En: Program and abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2003; Chicago, Illinois. Abstract H-1717."},{"key":"10.1157\/13089670_bib37","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00002030-200209270-00008","article-title":"Immune recovery is associated with persistent rise in HCV-RNA, infrequent liver test flares, and is not impaired by HCV in coinfected subjects","volume":"16","author":"Chung","year":"2002","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Grade 4 events are as important as AIDS events in the era of HAART","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1157\/13089670_bib39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00002030-200003100-00023","article-title":"The impact of coinfection with hepatitis C virus and HIV on tolerability of antiretroviral therapy","volume":"14","author":"Melvin","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/aid.2005.21.527","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient\/ physician choice in patients with hepatitis C coinfection","volume":"21","author":"Mocroft","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13089670_bib41","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/00002030-199810000-00025","article-title":"Hepatotoxicity after introduction of highly active antiretroviral therapy","volume":"12","author":"Rodr\u00edguez-Rosado","year":"1998","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib42","doi-asserted-by":"crossref","first-page":"F115","DOI":"10.1097\/00002030-199912030-00002","article-title":"Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998","volume":"13","author":"Saves","year":"1999","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1157\/13089670_bib44","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","article-title":"Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection","volume":"14","author":"Den Brinker","year":"2000","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib45","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.44.12.3451-3455.2000","article-title":"Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients","volume":"44","author":"Saves","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1157\/13089670_bib46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","article-title":"Risk factors for severe hepatic injury following the introduction of HAART","volume":"27","author":"N\u00fa\u00f1ez","year":"2001","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00126334-200107010-00017","article-title":"Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy","volume":"27","author":"Bonfanti","year":"2001","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00042560-200110010-00002","article-title":"Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART","volume":"28","author":"Monforte A de","year":"2001","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","article-title":"Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection","volume":"29","author":"Aceti","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00042560-200205010-00008","article-title":"Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy","volume":"30","author":"N\u00fa\u00f1ez","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0168-8278(01)00291-4","article-title":"Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases","volume":"36","author":"Clark","year":"2002","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jhep.2004.12.011","article-title":"Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients","volume":"42","author":"N\u00fa\u00f1ez","year":"2005","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00126334-200204010-00009","article-title":"Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999","volume":"29","author":"Selik","year":"2002","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"10.1157\/13089670_bib56","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1006\/viro.1998.9130","article-title":"Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters","volume":"244","author":"Beld","year":"1998","journal-title":"Virology"},{"key":"10.1157\/13089670_bib57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients co-infected with HIV and hepatitis C virus demonstrate higher levels of hepatic HCV-RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"10.1157\/13089670_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/clinids\/23.3.585","article-title":"Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV","volume":"23","author":"Soriano","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF02768746","article-title":"Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count","volume":"26","author":"Mauss","year":"1998","journal-title":"Infection"},{"key":"10.1157\/13089670_bib60","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/317644","article-title":"Liver fibrosis progression is related to CD4+ cell depletion in patients with hepatitis C and HIV coinfection","volume":"183","author":"Puoti","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib62","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1086\/367643","article-title":"Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV","volume":"36","author":"Mart\u00ednez-Sierra","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/380130","article-title":"Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C \u2013 a European collaborative study","volume":"38","author":"Mart\u00edn-Carbonero","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib64","first-page":"602","article-title":"Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with HIV. A multicenter hemophilia cohort study","volume":"6","author":"Eyster","year":"1993","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib65","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/BF01691375","article-title":"Influence of HIV type 1 infection on the natural history of chronic parenteral acquired hepatitis C","volume":"14","author":"S\u00e1nchez-Quijano","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1157\/13089670_bib66","first-page":"2563","article-title":"Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV","volume":"91","author":"Rockstroh","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13089670_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"HIV infection modifies the natural history of chronic parenteral acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1572-0241.2001.03374.x","article-title":"Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C","volume":"96","author":"Garc\u00eda-Samaniego","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13089670_bib69","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200411190-00009","article-title":"Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome","volume":"18","author":"Puoti","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib70","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)05413-5","article-title":"Mortality from liver cancer and liver disease in hemophiliac men and boys in the UK given blood product contaminated with hepatitis C","volume":"350","author":"Darby","year":"1997","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00126334-200007010-00003","article-title":"Mortality for liver disease in patients with HIV-infection: a cohort study","volume":"24","author":"Puoti","year":"2000","journal-title":"J Acquir Immun Defic Syndr"},{"key":"10.1157\/13089670_bib72","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10096-002-0823-0","article-title":"Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-1-infected patients receiving potent antiretroviral therapy","volume":"21","author":"Mac\u00edas","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1157\/13089670_bib73","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1468-1293.2002.00117.x","article-title":"Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999","volume":"3","author":"Bonnet","year":"2002","journal-title":"HIV Med"},{"key":"10.1157\/13089670_bib74","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib75","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1097\/00002030-200410210-00008","article-title":"Survival in patients with HIV infection and viral hepatitis B or C","volume":"18","author":"Bonacini","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in HIV and hepatitis C virus coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine","volume":"18","author":"Macias","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib78","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/aid.2004.20.1293","article-title":"Advanced liver fibrosis in HIV\/HCV-coinfected patients on antiretroviral therapy","volume":"20","author":"Fuster","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13089670_bib79","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated interferon-a2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"P\u00e9rez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002030-200401020-00007","article-title":"Early HCV dynamics on peg-interferon and ribavirin in HIV\/HCV coinfection: indications for the investigation of new treatment approaches","volume":"18","author":"Ballesteros","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002030-200401020-00008","article-title":"Pegylated interferon-a2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients","volume":"18","author":"Moreno","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib82","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13089670_bib83","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1157\/13089670_bib84","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13089670_bib85","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib86","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/088922204323048096","article-title":"Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients","volume":"20","author":"Soriano","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1157\/13089670_bib87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","article-title":"Viral kinetics in hepatitis C or hepatitis C\/HIV-infected patients","volume":"128","author":"Sherman","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1157\/13089670_bib88","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1086\/379334","article-title":"Pre-treatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection","volume":"188","author":"Vrolijk","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib89","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib90","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1157\/13089670_bib91","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.280.24.2088","article-title":"Pre-treatment evaluation of chronic hepatitis C. Risks, benefits, and costs","volume":"280","author":"Wong","year":"1998","journal-title":"JAMA"},{"key":"10.1157\/13089670_bib92","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1097\/00002030-200303280-00015","article-title":"Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?","volume":"17","author":"Soriano","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib93","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1053\/jhep.2001.25884","article-title":"To biopsy or not to biopsy","volume":"34","author":"Spinzi","year":"2001","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib94","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/hep.510340232","article-title":"To biopsy or not to biopsy","volume":"34","author":"Andriulli","year":"2001","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1157\/13089670_bib95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.1840360720","article-title":"The role of liver biopsy in chronic hepatitis C","volume":"36","author":"Dienstag","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib96","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib97","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib98","unstructured":"Sulkowski M, Mehta S, Torbenson M, Moore R, Thomas D. Unexpected significant liver disease among HIV\/HCV-coinfected persons with minimal fibrosis on initial liver biopsy. 12th CROI, Boston, February 2005 [abstract 121]."},{"key":"10.1157\/13089670_bib99","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1001\/archinte.162.22.2545","article-title":"Treatment for hepatitis C virus in HIV-infected patients: clinical benefits and cost-effectiveness","volume":"162","author":"Kuehne","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1157\/13089670_bib100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib101","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1157\/13089670_bib102","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00002030-200303280-00010","article-title":"Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients","volume":"17","author":"Myers","year":"2003","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib103","unstructured":"Sterling R, Lissen E, Clumeck N. Can routine non-invasive tests predict liver histology in HIV\/HCV co-infection? Analysis of patients entering the APRICOT. 12th CROI, Boston, February 2005 [abstract 120]."},{"key":"10.1157\/13089670_bib104","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/hep.20139","article-title":"Host factors and failure of interferon treatment in hepatitis C virus","volume":"39","author":"Gao","year":"2004","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-140-5-200403020-00033","article-title":"Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?","volume":"140","author":"Zeuzem","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1157\/13089670_bib106","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/0140-6736(93)91248-K","article-title":"Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection","volume":"341","author":"Vento","year":"1993","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib107","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/0140-6736(93)90736-Z","article-title":"Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients","volume":"341","author":"Pesce","year":"1993","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib108","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/135965350400900616","article-title":"Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1157\/13089670_bib109","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(02)00010-8","article-title":"Treating hepatitis C in methadone maintenance patients: an interim analysis","volume":"67","author":"Sylvestre","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1157\/13089670_bib110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1157\/13089670_bib111","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.1840360727","article-title":"Prevention and treatment of hepatitis C in injecting drug users","volume":"36","author":"Edlin","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib112","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1053\/gast.2002.1232082","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13089670_bib113","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib114","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","article-title":"HCV and HIV dynamics during HCV treatment in HIV\/HCV coinfection","volume":"188","author":"Torriani","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/135965350400900411","article-title":"Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1157\/13089670_bib116","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/135965350501000512","article-title":"Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C","volume":"10","author":"N\u00fa\u00f1ez","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1157\/13089670_bib117","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/jhep.2003.50107","article-title":"Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases","volume":"37","author":"Buti","year":"2003","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib118","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"issue":"Suppl","key":"10.1157\/13089670_bib119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.1840360709","article-title":"Use and interpretation of virological tests for hepatitis C","volume":"36","author":"Pawlotsky","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jhep.2003.12.017","article-title":"Reduction of relapse rates by 18-month treatment in chronic hepatitis C: a Benelux randomized trial in 300 patients","volume":"40","author":"Brouwer","year":"2004","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib121","unstructured":"N\u00fa\u00f1ez M, Maida I, Berd\u00fan M, Soriano V. Efficacy and safety of pegylated interferon alpha-2a plus ribavirin for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. 44th ICAAC; Washington, DC; October 2004 [abstract V-1148]."},{"key":"10.1157\/13089670_bib122","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib123","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modeling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1157\/13089670_bib124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1086\/340199","article-title":"Treatment of hepatitis C and anemia in HIV-infected patients","volume":"185","author":"Dieterich","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1157\/13089670_bib125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0168-8278(01)00110-6","article-title":"Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomised trial","volume":"35","author":"Alri","year":"2001","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib126","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","article-title":"Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach","volume":"34","author":"Camma","year":"2001","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib127","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/gast.2002.34785","article-title":"Interferon therapy prolongs life expectancy among chronic hepatitis C patients","volume":"123","author":"Yoshida","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13089670_bib128","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/00002030-199411000-00016","article-title":"CD4+ T lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C","volume":"8","author":"Soriano","year":"1994","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1157\/13089670_bib130","first-page":"150","article-title":"Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies","volume":"3","author":"Moyle","year":"2001","journal-title":"AIDS Rev"},{"key":"10.1157\/13089670_bib131","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/135965350501000410","article-title":"Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin","volume":"10","author":"De Mendoza","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1157\/13089670_bib132","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/00002030-200409030-00002","article-title":"Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrosis during interferon therapy","volume":"18","author":"Mauss","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib133","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.qai.0000170034.90438.68","article-title":"Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV\/hepatitis C virus-coinfected patients","volume":"39","author":"Rendon","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl","key":"10.1157\/13089670_bib134","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1157\/13089670_bib135","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1157\/13089670_bib136","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1053\/j.gastro.2004.01.027","article-title":"Epoetin alfa maintains ribavirin dose in HCV-infected patients. A prospective, double-blind randomized controlled study","volume":"126","author":"Afdhal","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1157\/13089670_bib137","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(04)90479-5","article-title":"Safety and efficacy of Viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-na\u00efve patients","volume":"40","author":"Gish","year":"2004","journal-title":"J Hepatol"},{"key":"10.1157\/13089670_bib138","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/135965350400900604","article-title":"Depressive symptoms after initiation of interferon therapy in HIV-infected patients with chronic hepatitis C","volume":"9","author":"Laguno","year":"2004","journal-title":"Antivir Ther"},{"issue":"Suppl 2","key":"10.1157\/13089670_bib139","first-page":"A726","article-title":"HCV evaluation and treatment can be improved by a multidisciplinary HIV\/HCV co-infection program: results from the first year of a program co-located at an urban HIV primary care clinic","volume":"128","author":"Zingman","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1157\/13089670_bib140","unstructured":"Breilh D. Plasma target concentration of ribavirin in HCV\/HIV-co-infected patients. 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, 2005. Boston, MA [abstract 928]."},{"key":"10.1157\/13089670_bib141","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1086\/382279","article-title":"A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus","volume":"189","author":"Drusano","year":"2004","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1157\/13089670_bib142","first-page":"A682","article-title":"Multicenter pilot study to assess the efficacy and safety of prolonging treatment with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) in HIV and HCV coinfected patients without early virological response","volume":"128","author":"Planas","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1157\/13089670_bib143","unstructured":"N\u00fa\u00f1ez M, Maida I, Berd\u00fan A. Efficacy and safety of pegInterferon-a-2a plus ribavirin (pegIFN + RBV) for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. The virological response obtained at the end of treatment is among the highest reported so far in this population. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract V-1148]."},{"key":"10.1157\/13089670_bib144","first-page":"686","article-title":"Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection","volume":"191","author":"Glesby","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1157\/13089670_bib145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200401020-00009","article-title":"Pegylated interferon alpha-2b and ribavirin in HIV\/hepatitis C virus-co-infected non-responders and relapdsers to IfN-based therapy","volume":"18","author":"Myers","year":"2004","journal-title":"AIDS"},{"key":"10.1157\/13089670_bib146","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X06737934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X06737934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T17:46:09Z","timestamp":1683481569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X06737934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":146,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0213005X06737934"],"URL":"https:\/\/doi.org\/10.1157\/13089670","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}